FDA Inspection 1233031 — Eurofins BioPharma Product Testing Sweden AB
The FDA completed an inspection of Eurofins BioPharma Product Testing Sweden AB on December 8, 2022 in Uppsala. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- December 8, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Uppsala (Sweden)
Additional Details
Mutual Recognition Agreement (MRA)